Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial

Ziqi Wan, Miao Chen, Bing Han, Ziqi Wan, Miao Chen, Bing Han

Abstract

Introduction: The therapeutic options for thrombocytopenia in non-severe aplastic anaemia (NSAA) are limited. Avatrombopag (AVA) is prescribed for thrombocytopenic diseases but not for NSAA.

Methods: Herein, we conducted a phase 2, non-randomized, single-arm trial to explore the efficacy and safety of AVA in refractory/relapsed/intolerant NSAA. AVA dose was initiated at 20 mg/d and titrated to a maximum of 60 mg/d. The primary endpoint was the haematological response at 3 months.

Results: Twenty-five patients were analyzed. The overall response rate (ORR) at 3 months was 56% (14/25), with 12% (3/25) achieving a complete response (CR). At a median follow-up of 7 (3-10) months, the OR and CR rates were 52% and 20%, respectively. Responders had a shorter duration of diagnosis of AVA administration than non-responders (10 (6-80) vs 37 (6-480) months, p = 0.027) and belonged to the relapsed/intolerant NSAA type (71% vs 27%, p = 0.047); 44% (8/18) patients previously treated with eltrombopag before enrollment responded at 3 months, with an average prior eltrombopag dose of median 72.5 (50-100) mg/d and an average AVA dose for a response of median 43.5 (20-60) mg/d. 3-month ORR had no significant correlation with eltrombopag exposure (p = 0.09), prior eltrombopag length (R2=0.11), or cumulative eltrombopag dose (R2=0.30). Only one patient relapsed after stopping AVA for 1 month. No serious AVA-related side effects or clone evolution were detected.

Conclusion: AVA is effective and well-tolerated in NSAA patients who are refractory, relapsed, or intolerant to CsA/tacrolimus ± eltrombopag. Earlier treatment and relapsed/intolerant AA may show a better short-term response rate. More studies are needed to define the optimal dose and the long-term efficacy (NCT04728789).

Keywords: Non-severe aplastic anemia; avatrombopag; efficacy; side effects; switch.

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
The CONSORT flow diagram. 30 patients were assessed and 1 was excluded because of developing secondary MDS from AA. Twenty-nine eligible patients were enrolled and allocated to receive AVA, as the intention-to-treat group. Four patients were treated with AVA for less than two months, either due to loss of follow-up (n = 3) or withdrawal of consent (n = 1). Twenty-five patients were included in the efficacy analysis.
Figure 2.
Figure 2.
Venn diagrams presenting the number of patients with the response for one or more lineages at 3 months (left) and last follow-up (right) at 3 months, 7 patients showed improvement in one lineage, 3 in two lineages, and 4 in three lineages. At a median of 7 (3–10) months follow-up, 11 patients showed a platelet response; 9 showed a haemoglobin response, and 7 showed a neutrophil response.
Figure 3.
Figure 3.
The longitudinal measurement of platelet (PLT, A), haemoglobin (HGB, B), and neutrophil (NEU, C) in responders. At 3 months, 44% (11/25) patients showed platelet response, 37% (7/19) showed haemoglobin response, and 54% (7/13) showed neutrophil response. At 6 months, 58% (7/12) patients showed platelet response, 55% (6/11) showed haemoglobin response, and 83% (5/6) showed neutrophil response. At the last follow-up, 44% (11/25) of patients showed platelet response. 47% (9/19) of patients showed haemoglobin response. 54% (7/13) of patients showed a neutrophil response. One patient who achieved PR after 2-months of AVA treatment and maintenance for 1 month (Figure 3(A), patient no. 19) relapsed after 1 month of stopping AVA.
Figure 4.
Figure 4.
Relationship between prior eltrombopag (EPAG) and 3-month overall response rate (ORR) to avatrombopag (AVA). 18 (72%) of the 25 patients were previously treated with EPAG for 8 (1–36) months at 72.5 (25–100) mg/d dosage; 44% (8/18) responded to AVA at 3 months. (A) Prior length of using EPAG showed no significant linear relationship with the 3-month ORR of AVA (R2=0.11). (B) There is no significant correlation between the previous cumulative EPAG dose and the 3-month ORR for AVA (R2=0.30).

References

    1. Young NS. Aplastic anemia. N Engl J Med. 2018;379(17):1–13. doi: 10.1056/NEJMra1413485.
    1. Li SS, Hsu YT, Chang C, et al. . Incidence and treatment outcome of aplastic anemia in Taiwan-real-world data from single-institute experience and a nationwide population-based database. Ann Hematol. 2019;98(1):29–39. doi: 10.1007/s00277-018-3486-3.
    1. Vaht K, Göransson M, Carlson K, et al. . Incidence and outcome of acquired aplastic anemia: real-world data from patients diagnosed in Sweden from 2000–2011. Haematologica. 2017;102(10):1683–1690. doi: 10.3324/haematol.2017.169862.
    1. Norasetthada L, Wongkhantee S, Chaipokam J, et al. . Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study. Ann Hematol. 2021;100(10):2443–2452. doi: 10.1007/s00277-021-04566-0.
    1. Zhang XT, Wang X, Cao J, et al. . Treatment outcome of 301 aplastic anemia patients in China: a 10-year follow-up and real-world data from single institute experience. Hematology. 2021;26(1):1025–1030. doi: 10.1080/16078454.2021.2009646.
    1. Killick SB, Bown N, Cavenagh J, et al. . Guidelines for the diagnosis and management of adult aplastic anaemia. Br J Haematol. 2016;172(2):187–207. doi: 10.1111/bjh.13853.
    1. Marsh J, Schrezenmeier H, Marin P, et al. . Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) severe aplastic anaemia working party. Blood. 1999;93(7):2191–2195. doi: 10.1182/blood.V93.7.2191.
    1. Townsley DM, Scheinberg P, Winkler T, et al. . Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017;376(16):1540–1550. doi: 10.1056/NEJMoa1613878.
    1. Ecsedi M, Lengline É, Knol-Bout C, et al. . Use of eltrombopag in aplastic anemia in Europe. Ann Hematol. 2019;98(6):1341–1350. doi: 10.1007/s00277-019-03652-8.
    1. Scheinberg P. Activity of eltrombopag in severe aplastic anemia. Blood Adv. 2018;2(21):3054–3062. doi: 10.1182/bloodadvances.2018020248.
    1. Fattizzo B, Levati G, Cassin R, et al. . Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation. Drugs. 2019;79(12):1305–1319. doi: 10.1007/s40265-019-01159-0.
    1. Fan X, Desmond R, Winkler T, et al. . Eltrombopag for patients with moderate aplastic anemia or uni-lineage cytopenias. Blood Adv. 2020;4(8):1700–1710. doi: 10.1182/bloodadvances.2020001657.
    1. Shirley M. Avatrombopag: first global approval. Drugs. 2018;78(11):1163–1168. doi: 10.1007/s40265-018-0949-8.
    1. Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Reviews. 2022;53:100909. doi: 10.1016/j.blre.2021.100909.
    1. Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. . AKR-501 (YM477) in combination with thrombopoietin enhances human megakaryocytopoiesis. Exp Hematol. 2008;36(10):1337–1342. doi: 10.1016/j.exphem.2008.04.020.
    1. Kuter DJ. New thrombopoietic growth factors. Blood. 2007;109(11):4607–4616. doi: 10.1182/blood-2006-10-019315.
    1. Michelson AD, Smolensky Koganov E, Forde EE, et al. . Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. J Thromb Haemost. 2018;16(12):2515–2519. doi: 10.1111/jth.14295.
    1. Wojciechowski P, Wilson K, Nazir J, et al. . Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: a systematic literature review and network meta-analysis. Adv Ther. 2021;38(6):3113–3128. doi: 10.1007/s12325-021-01752-4.
    1. Virk ZM, Kuter DJ, Al-Samkari H.. An evaluation of avatrombopag for the treatment of thrombocytopenia. Expert Opin Pharmacother. 2021;22(3):273–280. doi: 10.1080/14656566.2020.1841748.
    1. Cheloff AZ, Al-Samkari H.. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease. J Blood Med. 2019;10:313–321. doi: 10.2147/JBM.S191790.
    1. Al-Samkari H, Kuter DJ.. Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719841735. doi: 10.1177/2040620719841735.
    1. Jurczak W, Chojnowski K, Mayer J, et al. . Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479–490. doi: 10.1111/bjh.15573.
    1. Bussel JB, Kuter DJ, Aledort LM, et al. . A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123(25):3887–3894. doi: 10.1182/blood-2013-07-514398.
    1. Długosz-Danecka M, Zdziarska J, Jurczak W.. Avatrombopag for the treatment of immune thrombocytopenia. Expert Rev Clin Immunol. 2019;15(4):327–339. doi: 10.1080/1744666X.2019.1587294.
    1. Henter JI, Horne A, Aricó M, et al. . HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124–131. doi: 10.1002/pbc.21039.
    1. Fardet L, Galicier L, Lambotte O, et al. . Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613–2620. doi: 10.1002/art.38690.
    1. Health UDo, Services H . Common terminology criteria for adverse events. Version 5.0. Published 2017 Nov 27. 2020.
    1. Olnes MJ, Scheinberg P, Calvo KR, et al. . Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012;367(1):11–19. doi: 10.1056/NEJMoa1200931.
    1. Xu H, Cai R.. Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease. Expert Rev Clin Pharmacol. 2019;12(9):859–865. doi: 10.1080/17512433.2019.1649137.
    1. Scharf RE. Thrombocytopenia and hemostatic changes in acute and chronic liver disease: pathophysiology, clinical and laboratory features, and management. JCM. 2021;10(7):1530. doi: 10.3390/jcm10071530.
    1. Terrault N, Chen YC, Izumi N, et al. . Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):705–718. doi: 10.1053/j.gastro.2018.05.025.
    1. Nilles KM, Flamm SL.. Thrombocytopenia in chronic liver disease: new management strategies. Clin Liver Dis. 2020;24(3):437–451. doi: 10.1016/j.cld.2020.04.009.
    1. Gilreath J, Lo M, Bubalo J.. Thrombopoietin receptor agonists (TPO-RAs): drug class considerations for pharmacists. Drugs. 2021;81(11):1285–1305. doi: 10.1007/s40265-021-01553-7.
    1. Ghanima W, Cooper N, Rodeghiero F, et al. . Thrombopoietin receptor agonists: ten years later. Haematologica. 2019;104(6):1112–1123. doi: 10.3324/haematol.2018.212845.
    1. Khellaf M, Viallard JF, Hamidou M, et al. . A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013;98(6):881–887. doi: 10.3324/haematol.2012.074633.
    1. González-Porras JR, Godeau B, Carpenedo M.. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719837906. doi: 10.1177/2040620719837906.
    1. Kuter DJ, Tarantino MD, Lawrence T.. Clinical overview and practical considerations for optimizing romiplostim therapy in patients with immune thrombocytopenia. Blood Reviews. 2021;49:100811. doi: 10.1016/j.blre.2021.100811.
    1. Birocchi S, Podda GM, Manzoni M, et al. . Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets. 2021;32(2):216–226. doi: 10.1080/09537104.2020.1745168.
    1. Al-Samkari H, Nagalla S.. Efficacy and safety evaluation of avatrombopag in immune thrombocytopenia: analyses of a phase III study and long-term extension. Platelets. 2022;33(2):257–264. doi: 10.1080/09537104.2021.1881952.
    1. Agarwal N, Mangla A.. Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review. Ther Adv Hematol. 2021;12:20406207211001139. doi: 10.1177/20406207211001139.
    1. Fukushima-Shintani M, Suzuki K, Iwatsuki Y, et al. . AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist. Eur J Haematol. 2009;82(4):247–254. doi: 10.1111/j.1600-0609.2008.01198.x.
    1. Markham A. Avatrombopag: a review in thrombocytopenia. Drugs. 2021;81(16):1905–1913. doi: 10.1007/s40265-021-01613-y.
    1. Syed YY. Hetrombopag: first approval. Drugs. 2021;81(13):1581–1585. doi: 10.1007/s40265-021-01575-1.
    1. Young DJ, Fan X, Groarke EM, et al. . Long-term eltrombopag for bone marrow failure depletes iron. American J Hematol. 2022;97(6):791–801. doi: 10.1002/ajh.26543.
    1. Yang Y, Yang WR, Wu ZJ, et al. . Delayed hematologic response to immunosuppressive therapy in severe aplastic anemia. Zhonghua Xue Ye Xue Za Zhi. 2016;37(12):1038–1043.
    1. Patel BA, Groarke EM, Lotter J, et al. . Long-term outcomes in patients with severe aplastic anemia treated with immunosuppression and eltrombopag: a phase 2 study. Blood. 2022;139(1):34–43. doi: 10.1182/blood.2021012130.
    1. Frickhofen N, Kaltwasser JP, Schrezenmeier H, et al. . Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The german aplastic anemia study group. N Engl J Med. 1991;324(19):1297–1304. doi: 10.1056/NEJM199105093241901.
    1. Lee SE, Yahng SA, Cho BS, et al. . Improvement in hematopoiesis after iron chelation therapy with deferasirox in patients with aplastic anemia. Acta Haematol. 2013;129(2):72–77. doi: 10.1159/000342772.
    1. Zaimoku Y, Patel BA, Shalhoub R, et al. . Predicting response of severe aplastic anemia to immunosuppression combined with eltrombopag. haematol. 2021;107(1):126–133. doi: 10.3324/haematol.2021.278413.
    1. Hitchcock IS, Kaushansky K.. Thrombopoietin from beginning to end. Br J Haematol. 2014;165(2):259–268. doi: 10.1111/bjh.12772.
    1. Abe M, Suzuki K, Sakata C, et al. . Pharmacological profile of AS1670542, a novel orally-active human thrombopoietin receptor agonist. Eur J Pharmacol. 2011;650(1):58–63. doi: 10.1016/j.ejphar.2010.09.072.
    1. EHA 2021 . Virtual congress abstract book. HemaSphere. 2021;5(S2):548.
    1. Bussel JB, Cheng G, Saleh MN, et al. . Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357(22):2237–2247. doi: 10.1056/NEJMoa073275.
    1. Mishra K, Jandial A, Lad D, et al. . Cost and complications are limitations in resource-constrained settings for equine anti-thymocyte globulin. Eur J Haematol. 2018;101(3):421. doi: 10.1111/ejh.13125.
    1. Saab S, Brown RS. Jr.. Management of thrombocytopenia in patients with chronic liver disease. Dig Dis Sci. 2019;64(10):2757–2768. doi: 10.1007/s10620-019-05615-5.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe